CN101062120A - Medicine for curing waist and leg pain and its preparing method - Google Patents
Medicine for curing waist and leg pain and its preparing method Download PDFInfo
- Publication number
- CN101062120A CN101062120A CNA2007100544392A CN200710054439A CN101062120A CN 101062120 A CN101062120 A CN 101062120A CN A2007100544392 A CNA2007100544392 A CN A2007100544392A CN 200710054439 A CN200710054439 A CN 200710054439A CN 101062120 A CN101062120 A CN 101062120A
- Authority
- CN
- China
- Prior art keywords
- grams
- radix
- medicine
- ethanol
- rhizoma rhei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a pharmaceutical composition for treating waist and leg pains and process for preparation, wherein the medicament is prepared from wood louse, frankincense, myrrh, native copper, safflower, drynaria, rhubarb horsetails, borax and Chinese angelica root through steps of disintegrating, concentrating, granulating, and making capsule with pharmaceutically acceptable carriers or adjuvant.
Description
Technical field
The present invention relates to medicinal preparation for oral administration for the treatment of lumbago and skelalgia and preparation method thereof.
Background technology
All the time, it all is clinical common frequently-occurring disease that chronic lumbago and skelalgia, rheumatism numbness are ached, and domestic rheumatisant is near 200,000,000.More the patient see and be lumbar strain, lumbar strain, prolapse of lumbar intervertebral disc, rheumatic arthritis etc., do not heal general for a long time, outbreak repeatedly, and the patient is subjected to ailingly to torment for a long time, puzzlement.Survey data shows, the integrated marketing volume of 2003,2004,2005,2006 antirheumatics reaches 10.5 hundred million, 20.5 hundred million, 3,000,000,000,37.3 hundred million yuan respectively, the market development space is very wide, though the medicine for the treatment of on the market is a lot, but mainly based on Western medicine and Chinese medicine patch unguentum, only can the respite symptom, ease the pain, really can reach treating both the principal and secondary aspects of a disease, onset is rapid, evident in efficacy, toxic and side effects is little kind is actually rare.
Existing SHUJIN DINGTONG PIAN is recorded the 15 of the Sanitation Ministry medicine standard, the painful effect of this Drug therapy traumatic injury, chronic lumbago and skelalgia, rheumatism numbness is remarkable, but discover through us, this SHUJIN DINGTONG PIAN is owing to borax, Pyritum are higher, plumbous, arsenic content severe overweight, take easy accumulate poisoning for a long time, erious adverse reaction; And preparation method is backward, and product quality and curative effect be cannot say for sure to demonstrate,prove.
Summary of the invention
The objective of the invention is at the problem of above-mentioned existence and the medicine of a kind for the treatment of both the principal and secondary aspects of a disease, onset is rapid, evident in efficacy, toxic and side effects is little treatment lumbago and skelalgia is provided.It is according to traditional Chinese medicine theory, adopt Eupolyphaga Seu Steleophaga, Olibanum (processed), Myrrha (processed), Pyritum (calcined), Flos Carthami, Rhizoma Drynariae, Radix Et Rhizoma Rhei, Borax(calcined), when being classified as the medicine that raw material is processed into through the science compatibility, compare with former SHUJIN DINGTONG PIAN, this drug manufacture technology is simple, be easy to take, evident in efficacy; Borax, Pyritum are less, and life-time service is convenient, toxic and side effects is little, is a kind of medicine of ideal treatment lumbago and skelalgia.
The object of the present invention is achieved like this:
The medicine of treatment lumbago and skelalgia of the present invention is made by following raw material of Chinese medicine: Eupolyphaga Seu Steleophaga 850 grams, Olibanum (processed) 400 grams, Myrrha (processed) 400 grams, Pyritum (calcined) 250 grams, Flos Carthami 450 grams, Rhizoma Drynariae 550 grams, Radix Et Rhizoma Rhei 750 grams, Borax(calcined) 250 grams, Radix Angelicae Sinensis 250 grams.
The medicine of treatment lumbago and skelalgia of the present invention is prepared from as follows: Radix Et Rhizoma Rhei, Borax, Pyritum, Olibanum, Myrrha mixed powder are broken into fine powder; Radix Angelicae Sinensis adds 6～12 times of amounts of ethanol respectively with 60～90% alcohol reflux 2～3 times, and three flavors such as all the other Flos Carthamis are with 50～80% alcohol reflux 2～3 times, add ethanol 6-12 respectively and doubly measure, merge above extracting solution, filter, reclaim ethanol, concentrating under reduced pressure becomes the cream of relative density 1.05～1.30 (55 ℃), and fine powders such as cream and above-mentioned Radix Et Rhizoma Rhei are mixed, and granulates, dry, add adjuvant, mixing incapsulates.
Further, the medicine of treatment lumbago and skelalgia of the present invention is prepared from as follows: Radix Et Rhizoma Rhei, Borax, Pyritum, Olibanum, Myrrha mixed powder are broken into fine powder; Radix Angelicae Sinensis adds 8,6 times of amounts of ethanol respectively with 70% alcohol reflux 2 times, and three flavors such as all the other Flos Carthamis are with 60% alcohol reflux 2 times, add 10,8 times of amounts of ethanol, merge above extracting solution, filter, reclaim ethanol, concentrating under reduced pressure becomes the cream of relative density 1.10～1.25 (55 ℃), and fine powders such as cream and above-mentioned Radix Et Rhizoma Rhei are mixed, and granulates, dry, add adjuvant, mixing incapsulates.
Further, with pulverizer Radix Et Rhizoma Rhei, Borax, Pyritum, Olibanum, Myrrha mixed powder are broken into fine powder earlier, the messenger drug powder fineness reaches more than 80 orders, carries out micronizing through various superfine communication techniques again, makes the mean diameter of medicated powder be less than 80 μ m.
Further, the temperature of usefulness alcohol reflux and extracting solution recovery ethanol, concentrating under reduced pressure must not be greater than 60 ℃.
Characteristics of the present invention are: 1, five kinds of crude drug of the present invention adopt the preparation method of micronizing, preferably with micronizing equipment sealing better, medicated powder yield height, pulverize the very little micronizing unit of loss and pulverize, fineness surpasses more than 96% less than the fine powder of 80 μ m after testing.The product that makes by micronizing has been avoided the loss of effective components that causes because of being heated, makes cell wall or membranolysis, accelerates the dissolution of effective ingredient, has improved product quality and clinical efficacy; 2, the present invention's capsule bioavailability height, disintegrate of making is fast, and be fast than the tablet produce effects, good absorbing, cure rate height, evident in efficacy; 3, plumbous, arsenic content is starkly lower than former SHUJIN DINGTONG PIAN, can avoid taking for a long time and accumulate the generation that causes poisoning and untoward reaction in human body; Prove through pharmacodynamics test that 4, medicine of the present invention has significant expelling wind and activating blood circulation dissipating blood stasis, the effect of collateral dredging reducing swelling and alleviating pain; 5, Clinical Practice proves, the total effective rate of treatment rheumatoid arthritis is 94.7%, and the total effective rate of treatment rheumatic arthritis is 96.1%, and the total effective rate of treatment fracture is 96.6%.Specific as follows:
The mensuration of test example 1 lead, cadmium, arsenic, hydrargyrum, copper
Get medicine of the present invention and former SHUJIN DINGTONG PIAN, measure, the results are shown in Table one by lead, cadmium, arsenic, hydrargyrum, copper algoscopy (Chinese Pharmacopoeia appendix IX in 2005).
| Group | Lead/ppm | Cadmium/ppm | Arsenic/ppm | Hydrargyrum/ppm | Copper/ppm |
| Medicine of the present invention | 6.1 | 1.5 | 1.4 | 0.014 | 2.3 |
| Matched group | 58.2 | 2.6 | 71.6 | 0.021 | 16.1 |
Measurement result shows that the lead of medicine of the present invention, arsenic, copper are starkly lower than former SHUJIN DINGTONG PIAN.
Test example 2 pharmacodynamics tests
Experiment material:
1, animal rat, 8～10 ages in week, body weight 160 grams.
2, medicine: medicine of the present invention.
Experimental technique:
Get 60 rats, be divided into 3 groups at random, 20 every group.
1, matched group: give normal saline 20ml/kg.
2, of the present invention group: give medicine 6g/kg of the present invention.
More than each the group, be administered once every day, continuous 12 weeks, the situation of observing rat at any time, per two weeks weigh once, after 24 hours, do pathologic finding in the last administration.
Result of the test proves that the present invention has tangible promoting blood circulation to remove blood stasis, reducing swelling and alleviating pain effect to rat.
Test example 3, treatment rheumatoid arthritis, rheumatic arthritis, fracture patient 422 routine clinical reports
Materials and methods
One, object of study
Patient with rheumatoid arthritis:
1,75 examples are organized in treatment, 16 years old～68 years old age.
2, matched group 53 examples, 17～66 years old age.
Rheumatic arthritis patient:
1,102 examples are organized in treatment, 21 years old～62 years old age.
2, matched group 58 examples, 19～65 years old age.
Fracture patient:
1,89 examples are organized in treatment, 16 years old～68 years old age.
2, matched group 45 examples, 23～64 years old age.
Two, the method for administration and the course of treatment
Of the present invention group: obey 4 at every turn, obey every day 2 times, each month is a course of treatment.
Matched group: obey 4 of SHUJIN DINGTONG PIAN at every turn, obey every day 2 times, each month is a course of treatment.
The result
The total effective rate of Drug therapy rheumatoid arthritis of the present invention is 94.7%, is high than matched group 90.6%, sees Table two; The total effective rate of treatment rheumatic arthritis is 96.1%, is high than matched group 89.7%, sees Table three; The total effective rate of treatment fracture is 96.6%, is high than matched group 91.2%, sees Table four.
The clinical observation of table two Drug therapy rheumatoid arthritis of the present invention
| Group | Case load | Cure | Produce effects | Effectively | Invalid | Total effective rate |
| Medicine of the present invention | 75 | 40 | 25 | 6 | 4 | 94.7％ |
| Matched group | 53 | 26 | 17 | 5 | 5 | 90.6％ |
The clinical observation of table three Drug therapy rheumatic arthritis of the present invention
| Group | Case load | Cure | Produce effects | Effectively | Invalid | Total effective rate |
| Medicine of the present invention | 102 | 68 | 22 | 8 | 4 | 96.1％ |
| Matched group | 58 | 30 | 21 | 7 | 6 | 89.7％ |
The clinical observation of table four Drug therapy fracture of the present invention
| Group | Case load | Cure | Produce effects | Effectively | Invalid | Total effective rate |
| Medicine of the present invention | 89 | 59 | 20 | 7 | 3 | 96.6％ |
| Matched group | 45 | 26 | 13 | 6 | 4 | 91.2％ |
The specific embodiment
Further specify the present invention below by specific embodiment.
Embodiment 1
Eupolyphaga Seu Steleophaga 758 grams, Olibanum (processed) 455 grams, Myrrha (processed) 455 grams, Pyritum (calcined) 455 grams, Flos Carthami 455 grams, Rhizoma Drynariae 455 grams, Radix Et Rhizoma Rhei 455 grams, Borax(calcined) 455 grams, Radix Angelicae Sinensis 455 grams
Earlier with pulverizer Radix Et Rhizoma Rhei, Borax, Pyritum, Olibanum, Myrrha mixed powder are broken into fine powder, the messenger drug powder fineness reaches more than 80 orders, carries out micronizing through superfine communication technique again, makes the mean diameter of medicated powder reach 60～80 μ m; Radix Angelicae Sinensis is with 60% alcohol reflux 3 times, and temperature is not more than 80 ℃, adds 8,6 times of amounts of ethanol respectively, all the other Flos Carthamis etc. three flavor is with 80% alcohol reflux 3 times, and temperature is not more than 80 ℃, adds 8,6 times of amounts of ethanol, merge above extracting solution, filter, reclaim ethanol, temperature is not more than 80 ℃, and concentrating under reduced pressure becomes the cream of relative density 1.10～1.30 (55 ℃), and cream is mixed with fine powders such as above-mentioned Radix Et Rhizoma Rhei, granulate, drying adds adjuvant, mixing incapsulates.
Embodiment 2
Eupolyphaga Seu Steleophaga 800 grams, Olibanum (processed) 350 grams, Myrrha (processed) 350 grams, Pyritum (calcined) 350 grams, Flos Carthami 550 grams, Rhizoma Drynariae 450 grams, Radix Et Rhizoma Rhei 600 grams, Borax(calcined) 300 grams, Radix Angelicae Sinensis 350 grams.
Earlier with pulverizer Radix Et Rhizoma Rhei, Borax, Pyritum, Olibanum, Myrrha mixed powder are broken into fine powder, the messenger drug powder fineness reaches more than 80 orders, carries out micronizing through superfine communication technique again, makes the mean diameter of medicated powder be less than 20～40 μ m; Radix Angelicae Sinensis is with 70% alcohol reflux 3 times, and temperature is not more than 80 ℃, adds 8,6 times of amounts of ethanol respectively, all the other Flos Carthamis etc. three flavor is with 60% alcohol reflux 2 times, and temperature is not more than 80 ℃, adds 10,8 times of amounts of ethanol, merge above extracting solution, filter, reclaim ethanol, temperature is not more than 60 ℃, and concentrating under reduced pressure becomes the cream of relative density 1.05～1.25 (55 ℃), and cream is mixed with fine powders such as above-mentioned Radix Et Rhizoma Rhei, granulate, drying adds adjuvant, mixing incapsulates.
Embodiment 3
Eupolyphaga Seu Steleophaga 850 grams, Olibanum (processed) 400 grams, Myrrha (processed) 400 grams, Pyritum (calcined) 250 grams, Flos Carthami 450 grams, Rhizoma Drynariae 550 grams, Radix Et Rhizoma Rhei 750 grams, Borax(calcined) 250 grams, Radix Angelicae Sinensis 250 grams.
Earlier with pulverizer Radix Et Rhizoma Rhei, Borax, Pyritum, Olibanum, Myrrha mixed powder are broken into fine powder, the messenger drug powder fineness reaches more than 80 orders, carries out micronizing through superfine communication technique again, makes the mean diameter of medicated powder be less than 40～60 μ m; Radix Angelicae Sinensis is with 70% alcohol reflux 2 times, and temperature is not more than 60 ℃, adds 8,6 times of amounts of ethanol respectively, all the other Flos Carthamis etc. three flavor is with 60% alcohol reflux 2 times, and temperature is not more than 60 ℃, adds 10,8 times of amounts of ethanol, merge above extracting solution, filter, reclaim ethanol, temperature is not more than 60 ℃, and concentrating under reduced pressure becomes the cream of relative density 1.10～1.25 (55 ℃), and cream is mixed with fine powders such as above-mentioned Radix Et Rhizoma Rhei, granulate, drying adds adjuvant, mixing incapsulates.
Claims (5)
1, a kind of medicine for the treatment of lumbago and skelalgia is characterized in that it is the medicinal preparation for oral administration of being made by the raw material of following weight parts and pharmaceutically acceptable carrier or adjuvant: Eupolyphaga Seu Steleophaga 850 grams, Olibanum (processed) 400 grams, Myrrha (processed) 400 grams, Pyritum (calcined) 250 grams, Flos Carthami 450 grams, Rhizoma Drynariae 550 grams, Radix Et Rhizoma Rhei 750 grams, Borax(calcined) 250 grams, Radix Angelicae Sinensis 250 grams.
2, as claims 1 described medicine, it is characterized in that it is prepared from as follows: earlier Radix Et Rhizoma Rhei, Borax, Pyritum, Olibanum, Myrrha mixed powder are broken into fine powder; Radix Angelicae Sinensis adds 6～12 times of amounts of ethanol respectively with 60～90% alcohol reflux 2～3 times, and three flavors such as all the other Flos Carthamis are with 50～80% alcohol reflux 2～3 times, add ethanol 6-12 respectively and doubly measure, merge above extracting solution, filter, reclaim ethanol, concentrating under reduced pressure becomes the cream of relative density 1.05～1.30 (55 ℃), and fine powders such as cream and above-mentioned Radix Et Rhizoma Rhei are mixed, and granulates, dry, add adjuvant, mixing incapsulates.
3, as claims 1 or 2 described medicines, it is characterized in that it is prepared from as follows: earlier Radix Et Rhizoma Rhei, Borax, Pyritum, Olibanum, Myrrha mixed powder are broken into fine powder; Radix Angelicae Sinensis adds 8,6 times of amounts of ethanol respectively with 70% alcohol reflux 2 times, and three flavors such as all the other Flos Carthamis are with 60% alcohol reflux 2 times, add 10,8 times of amounts of ethanol, merge above extracting solution, filter, reclaim ethanol, concentrating under reduced pressure becomes the cream of relative density 1.10～1.25 (55 ℃), and fine powders such as cream and above-mentioned Radix Et Rhizoma Rhei are mixed, and granulates, dry, add adjuvant, mixing incapsulates.
4, as the preparation method of medicine as described in claims 2 or 3, it is characterized in that with pulverizer Radix Et Rhizoma Rhei, Borax, Pyritum, Olibanum, Myrrha mixed powder being broken into fine powder earlier, the messenger drug powder fineness reaches more than 80 orders, carry out micronizing through various superfine communication techniques again, make the mean diameter of medicated powder be less than 80 μ m.
5,, it is characterized in that the temperature of recovery ethanol, concentrating under reduced pressure with alcohol reflux and extracting solution must not be greater than 60 ℃ as the preparation method of medicine as described in claims 2 or 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100544392A CN101062120A (en) | 2007-05-23 | 2007-05-23 | Medicine for curing waist and leg pain and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100544392A CN101062120A (en) | 2007-05-23 | 2007-05-23 | Medicine for curing waist and leg pain and its preparing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101062120A true CN101062120A (en) | 2007-10-31 |
Family
ID=38963534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007100544392A Pending CN101062120A (en) | 2007-05-23 | 2007-05-23 | Medicine for curing waist and leg pain and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101062120A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103566266A (en) * | 2013-11-16 | 2014-02-12 | 王纯治 | Traditional Chinese medicine mixture for treating waist and leg rheumatalgia |
| CN106822511A (en) * | 2017-03-31 | 2017-06-13 | 湖北师范大学 | A kind of strong bone-joining powder |
-
2007
- 2007-05-23 CN CNA2007100544392A patent/CN101062120A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103566266A (en) * | 2013-11-16 | 2014-02-12 | 王纯治 | Traditional Chinese medicine mixture for treating waist and leg rheumatalgia |
| CN106822511A (en) * | 2017-03-31 | 2017-06-13 | 湖北师范大学 | A kind of strong bone-joining powder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1836720A (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| CN1704085A (en) | Pharmaceutical composition with immunoregulation function and method for preparing the same | |
| CN102058673B (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN101062120A (en) | Medicine for curing waist and leg pain and its preparing method | |
| CN1250264C (en) | Capsule for curing hyperplasia of mammary glands and its preparation method | |
| CN101028484A (en) | Chinese medicinal paste for treating tumor and its production | |
| CN1686423A (en) | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method | |
| CN1931213A (en) | Tuniclike psammosilene root extract and its prep. medicine composition and use | |
| CN1931276A (en) | Headache treating Chinese medicine composition and its prepn process | |
| CN1927315A (en) | Medicine for treating psoriasis mainly and its preparation method and use | |
| CN1468602A (en) | Application of naringin in preparing medicine for supporting treatment of SARS | |
| CN1686414A (en) | Wound dispelling swell dispersing tincture and its preparation method | |
| CN101301392B (en) | Chinese medicine for treating systemic lupus erythematosus and preparation thereof | |
| CN1248709C (en) | Chinese medicine prepn for stopping drug addiction | |
| CN1742854A (en) | Preparation of the pod of pagoda tree and preparing method thereof | |
| CN1250247C (en) | Luyang kidney yang strengthening Chinese traditional medicinal formula and its preparation | |
| CN1857492A (en) | Qingxie preparation and its preparing process | |
| CN1742820A (en) | Stomach-power Chinese medicine preparation and preparing method | |
| CN1813925A (en) | Chinese medicine formulation for treating pharynx and larynx disease and its preparing method | |
| CN1814272A (en) | Chinese medicine plaster for treating asthma and preparing method | |
| CN1475261A (en) | Medicine for treating gastral cavity pain and its preparation method | |
| CN102670740A (en) | Drug composition for treating soft tissue injuries and preparation process thereof | |
| CN103599281B (en) | Traditional Chinese medicinal composition for treating obsessive-compulsive disorder and application thereof | |
| CN1562177A (en) | Chinese materia medica preparation for treating hysteromyoma and preparation method | |
| CN1745802A (en) | Plaster for treating pain and prpearation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20071031 |